Cyclophosphamide

DNA damage inducible transcript 3 ; Homo sapiens







305 Article(s)
Download
PMID
Title
Pub. Year
#Total Relationships
1 34254266 Clinical impact of comprehensive geriatric assessment in patients aged 80 years and older with diffuse large B-cell lymphoma receiving rituximab-mini-CHOP: a single-institute retrospective study. 2022 Feb 1
2 34797531 Safety and efficacy of durvalumab with R-CHOP or R2-CHOP in untreated, high-risk DLBCL: a phase 2, open-label trial. 2022 Feb 1
3 34843406 Romidepsin Plus CHOP Versus CHOP in Patients With Previously Untreated Peripheral T-Cell Lymphoma: Results of the Ro-CHOP Phase III Study (Conducted by LYSA). 2022 Jan 20 1
4 35044836 TRAIL Score: A Simple Model to Predict Immunochemotherapy Tolerability in Patients With Diffuse Large B-Cell Lymphoma. 2022 Jan 1
5 35096395 Diffuse large B-cell lymphoma with uncommon cardiac invasion. 2022 1
6 35297262 Colonic infiltration of chronic lymphocytic leukemia with Hodgkin Reed Sternberg-like cells. 2022 Mar 17 1
7 35451406 Impact of pegfilgrastim approval on relative dose intensity and outcomes of R-CHOP for diffuse large B-cell lymphoma. 2022 Mar 11 1
8 35468783 Adding rituximab to chemotherapy for diffuse large B-cell lymphoma patients in Indonesia: a cost utility and budget impact analysis. 2022 Apr 25 1
9 35573753 COVID-19-Associated Pneumonia in a B-Cell-Depleted Patient With Non-Hodgkin Lymphoma: Recovery With Hyperimmune Plasma. 2022 Apr 1
10 33436910 Evaluation for pharmacokinetic exposure of cytotoxic anticancer drugs in elderly patients receiving (R-)CHOP therapy. 2021 Jan 12 3
11 33483276 Impact of Omission/Reduction of Vincristine From R-CHOP in Treatment of DLBCL. 2021 Mar 1
12 33573703 5-Hydroxymethylcytosine profiles of cfDNA are highly predictive of R-CHOP treatment response in diffuse large B cell lymphoma patients. 2021 Feb 11 1
13 33591324 A randomized phase 2/3 study of R-CHOP vs CHOP combined with dose-dense rituximab for DLBCL: the JCOG0601 trial. 2021 Feb 23 1
14 33592897 Long-term follow-up after rituximab plus bendamustine in a patient with relapsed or refractory hairy cell leukemia variant: A case report. 2021 Feb 5 1
15 33625586 Vinorelbine as substitute for vincristine in patients with diffuse large B cell lymphoma and vincristine-induced neuropathy. 2021 Sep 1
16 33688781 Progression-free survival at 24 months as a predictor of survival outcomes after CHOP treatment in patients with peripheral T-cell lymphoma: a single-center validation study in a Japanese population. 2021 Aug 1
17 33734921 R-CHOP compared to R-CHOP + X for newly diagnosed diffuse large B-cell lymphoma: a systematic review and meta-analysis. 2021 Jun 1
18 33944646 Burden of illness and treatment patterns among patients with peripheral T-cell lymphoma in the US healthcare setting. 2021 Jul 1
19 34124276 Suppression of DLBCL Progression by the E3 Ligase Trim35 Is Mediated by CLOCK Degradation and NK Cell Infiltration. 2021 1
20 34565287 Silencing Aurora-kinase-A (AURKA) reinforced the sensitivity of diffuse large B-cell lymphoma cells to cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) via suppressing β-Catenin and RAS-extracellular signal-regulated protein kinase (ERK1/2) pathway. 2021 Dec 2
21 34586105 Tafasitamab for refractory/relapsed diffuse large B-cell lymphoma. 2021 Sep 1
22 34732441 Clinicopathologic and Prognostic Significance of Bruton's Tyrosine Kinase Expression in Diffuse Large B-Cell Lymphoma. 2021 Nov 1
23 34745610 Intratumoral T-cell receptor repertoire is predictive of interim PET scan results in patients with diffuse large B-cell lymphoma treated with rituximab/cyclophosphamide/doxorubicin/prednisolone/vincristine (R-CHOP) chemoimmunotherapy. 2021 2
24 34765356 Vincristine-Induced Bilateral Vocal Cord Palsy in an Adult Male With Diffuse Large B-Cell Lymphoma. 2021 Oct 1
25 34895738 Complete response in a frail patient with high-grade B-cell lymphoma to only one cycle of R-CHOP or to prolonged COVID-19? 2021 Aug-Dec 1
26 34990525 Pegfilgrastim Prophylaxis is Effective in the Prevention of Febrile Neutropenia and Reduces Mortality in Patients Aged ≥75 Years with Diffuse Large B-Cell Lymphoma Treated with R-CHOP: A Prospective Cohort Study. 2021 Dec 30 1
27 31902733 Primary Dural Diffuse Large B-cell Lymphoma: A Comprehensive Review of Survival and Treatment Outcomes. 2020 Feb 1
28 32028388 Rare malignant ulcer related to primary intestinal diffuse large B-cell lymphoma: A case report. 2020 Feb 1
29 32042095 Identification of gene modules associated with survival of diffuse large B-cell lymphoma treated with CHOP-based chemotherapy. 2020 Oct 1
30 32112707 Double-Hit and Triple-Hit Follicular Lymphoma. 2020 Apr 15 1
31 32187361 Targeted sequencing in DLBCL, molecular subtypes, and outcomes: a Haematological Malignancy Research Network report. 2020 May 14 1
32 32250167 ENGINE: a Phase III randomized placebo controlled study of enzastaurin/R-CHOP as frontline therapy in high-risk diffuse large B-cell lymphoma patients with the genomic biomarker DGM1. 2020 May 1
33 32349779 CEOP/IVE/GDP alternating regimen compared with CEOP as the first-line therapy for newly diagnosed patients with peripheral T cell lymphoma: results from a phase 2, multicenter, randomized, controlled clinical trial. 2020 Apr 30 1
34 32417940 Progression of disease within 2 years (POD24) is a clinically relevant endpoint to identify high-risk follicular lymphoma patients in real life. 2020 Jul 1
35 32623836 The BCL-2 family protein inhibitor ABT-737 as an additional tool for the treatment of EBV-associated post-transplant lymphoproliferative disorders. 2020 Oct 1
36 32648457 Clinical characteristics and outcomes of patients with diffuse large B cell lymphoma treated with R-CHOP-like or CHOP-like regimens: an 8-year experience from a single center. 2020 Jul 1
37 32915975 Fractures are common within 18 months following first-line R-CHOP in older patients with diffuse large B-cell lymphoma. 2020 Sep 22 1
38 32994268 Transformation to plasmablastic lymphoma in CLL upon ibrutinib treatment. 2020 Sep 29 1
39 33093947 ACCEPT - combining acalabrutinib with rituximab, cyclophosphamide, doxorubicin, vincristine and prednisolone (R-CHOP) for Diffuse Large B-cell Lymphoma (DLBCL): study protocol for a Phase Ib/II open-label non-randomised clinical trial. 2020 1
40 33116822 Splenic Diffuse Red Pulp Small B-Cell Lymphoma with Gastrointestinal Hemorrhage: A Case Report and Literature Review. 2020 1
41 33230132 Liquid biopsy based on small extracellular vesicles predicts chemotherapy response of canine multicentric lymphomas. 2020 Nov 23 1
42 33233444 CITCO as an Adjuvant Facilitates CHOP-Based Lymphoma Treatment in hCAR-Transgenic Mice. 2020 Nov 21 1
43 33269174 DA-REPOCH Versus R-CHOP for the Treatment of Activated B-Cell Subtype Diffuse Large B-Cell Lymphoma: A Community Center Experience. 2020 Nov 26 1
44 33317571 New agents and regimens for diffuse large B cell lymphoma. 2020 Dec 14 1
45 30101679 Efficacy and tolerability of rituximab and reduced-dose cyclophosphamide, doxorubicin, vincristine, and prednisolone therapy for elderly patient with diffuse large B-cell lymphoma. 2019 Dec 1
46 30307363 Successful implementation of genomically based treatment of chemotherapy refractory peripheral T-cell lymphoma (PTCL). 2019 1
47 30689002 Cyclophosphamide dose adjustment based on body weight and albuminemia in elderly patients treated with R-mini-CHOP. 2019 Apr 1
48 31118164 R-CHOP preceded by blood-brain barrier permeabilization with engineered tumor necrosis factor-α in primary CNS lymphoma. 2019 Jul 18 1
49 31185769 Temporal trends in treatment and survival of older adult diffuse large B-Cell lymphoma patients in the SEER-Medicare linked database. 2019 Dec 1
50 31222719 Stand-alone intrathecal central nervous system (CNS) prophylaxis provide unclear benefit in reducing CNS relapse risk in elderly DLBCL patients treated with R-CHOP and is associated increased infection-related toxicity. 2019 Oct 1